Acorda Therapeutics Inc. (ACOR) Insider Sells $77,925.00 in Stock
Acorda Therapeutics Inc. (NASDAQ:ACOR) insider Jane Wasman sold 3,750 shares of the stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $20.78, for a total transaction of $77,925.00. Following the sale, the insider now directly owns 105,021 shares of the company’s stock, valued at approximately $2,182,336.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Jane Wasman also recently made the following trade(s):
- On Friday, September 23rd, Jane Wasman sold 500 shares of Acorda Therapeutics stock. The stock was sold at an average price of $27.32, for a total transaction of $13,660.00.
Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) opened at 20.67 on Thursday. The firm’s market cap is $952.68 million. The firm has a 50-day moving average of $24.29 and a 200-day moving average of $25.88. Acorda Therapeutics Inc. has a 52 week low of $20.18 and a 52 week high of $43.63.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.18 by $0.11. The company earned $127.45 million during the quarter, compared to the consensus estimate of $128.33 million. Acorda Therapeutics had a negative net margin of 1.08% and a positive return on equity of 1.00%. The business’s revenue was up 12.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.31 EPS. On average, analysts expect that Acorda Therapeutics Inc. will post $0.47 EPS for the current year.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Acorda Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 28th. Cowen and Company restated an “outperform” rating and set a $65.00 target price on shares of Acorda Therapeutics in a report on Thursday, August 25th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Leerink Swann began coverage on shares of Acorda Therapeutics in a report on Tuesday. They set a “market perform” rating and a $25.00 target price for the company. Finally, Stifel Nicolaus restated a “buy” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $39.63.
Several hedge funds have recently added to or reduced their stakes in the stock. Panagora Asset Management Inc. raised its stake in Acorda Therapeutics by 3.7% in the first quarter. Panagora Asset Management Inc. now owns 164,588 shares of the biopharmaceutical company’s stock valued at $4,353,000 after buying an additional 5,808 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Acorda Therapeutics during the first quarter valued at $291,000. Arrowgrass Capital Partners US LP bought a new stake in Acorda Therapeutics during the first quarter valued at $661,000. Jacobs Levy Equity Management Inc. bought a new stake in Acorda Therapeutics during the first quarter valued at $2,508,000. Finally, HBK Investments L P bought a new stake in Acorda Therapeutics during the first quarter valued at $1,108,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.